.png){kind=icon}
返回
A
Alessandro D. Santin
Yale University
70H指数
706论文数
1.9W被引数
收录论文 171
发表时间
.png){kind=icon}
Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes子宫内膜癌中滋养层细胞表面抗原2（TROP2）、叶酸受体α（FRα）和人类表皮生长因子受体2（HER2）的整合表达谱分析，涉及分子类别、基因组改变和组织学亚型.png)
Gynecologic Oncology.png)
Gynecologic OncologyIF4.1
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor雌激素受体降解剂Fulvestrant与RAF/MEK夹具Avutometinib及FAK抑制剂联合应用在低级别浆液性卵巢癌动物模型中的预临床疗效（该模型对化疗和芳香化酶抑制剂产生获得性耐药）
OAAI
OAAI分享收藏Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts达波妥昔单抗德鲁克坦（Dato-DXd）是一种靶向滋养层细胞表面抗原2（TROP2）的抗体药物偶联物（ADC），其对原代宫颈癌细胞系和异种移植瘤表现出有效的临床前活性。gynecologic oncology
gynecologic oncologyIF4.1
PREAI
分享收藏Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcomaDatopotamab deruxtecan，一种靶向TROP2的新型抗体偶联药物，其载荷为拓扑异构酶I抑制剂，在体外显示出对原发性及转移性子宫和卵巢TROP2过表达的癌肉瘤的活性。gynecologic oncology
gynecologic oncologyIF4.1
PREAI
分享收藏